This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
—Dr Flach suggests that my estimate of 10 000 new unhappy patients per year (1% of cases) with chronic, visually significant postcataract CME may be an underestimate because the two studies reviewed employed postoperative topical corticosteroid therapy.1,2 While it is possible that routine postoperative use of corticosteroids decreases the incidence of persistent aphakic or pseudophakic CME, we have no definite evidence to support this hypothesis, in regard to either angiographic or visually significant CME.3,4 However, virtually all cataract surgeons in the United States do indeed use a postoperative topical corticosteroid. Many patients are given topical corticosteroids indefinitely. Thus, an estimated rate of persistent, visually significant CME of approximately 1% to 2% seems appropriate.Dr Flach's next point is that the severity of the angiographic CME may not correlate with the patient's visual acuity. In their recently reported study, with small numbers of patients, Flach et al
Jampol LM. Cystoid Macular Edema Following Cataract Surgery-Reply. Arch Ophthalmol. 1989;107(2):166-167. doi:10.1001/archopht.1989.01070010172004